TuHURA Biosciences, Inc./NV
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
HURA$1.51-9.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
The following documents are filed as part of this Annual Report on Form 10-K:
(a)(1) Financial Statements
The list of consolidated financial statements set forth in the accompanying Index to the Consolidated Financial Statements at page F-1 of this Annual Report on Form 10-K is incorporated herein by reference. Such consolidated financial statements are filed as part of this Annual Report on Form 10-K.
(a)(2) Financial Statement Schedules
All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.
(a)(3) Exhibits
The following is a list of exhibits filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K.
| ExhibitNumber | Description |
| 1.1 | At-the-Market Offering Agreement, dated as of November 3, 2025, between TuHURA Biosciences, Inc. and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 1.2 to TuHURA Biosciences, Inc.’s Registration Statement on Form S-3 filed with the SEC on November 3, 2025 (Registration No. 333-291239) |
| 2.1†† | Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc., Kineta, Inc., Hura Merger Sub I, Inc., Hura Merger Sub II, LLC and Craig Philips (incorporated by reference to Exhibit 2.1 of TuHURA’s Current Report on Form 8-K filed with the SEC on December 12, 2024) |
| 2.2†† | Agreement and Plan of Merger, dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., Kayak Mergeco, Inc., and TuHURA Biosciences, Inc., as amended (incorporated by reference to Exhibit 2.1 of TuHURA’s (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K filed with the SEC on April 3, 2024) |
| 3.1 | Articles of Incorporation of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.), as amended (incorporated by reference to Exhibit 3.1 to TuHURA Biosciences, Inc.’s Registration Statement on Form S-1 filed with the SEC on August 12, 2025 (Registration No. 333-289532) |
| 3.2 | Amended and Restated Bylaws of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.) (incorporated by reference to Exhibit 3.1 to TuHURA’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022) |
| 4.1 | Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant issued in Series A Preferred Offering (incorporated by reference to Exhibit 4.12 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 4.2 | Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant, dated June 1, 2019, issued for advisory services (incorporated by reference to Exhibit 4.13 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 4.3 | Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant issued in Note Conversion Transaction (incorporated by reference to Exhibit 4.15 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 4.4 | Form of TuHURA Biosciences, Inc. (f/k/a Morphogenesis, Inc.) Common Stock Purchase Warrant issued in Series B Preferred Stock Offering (incorporated by reference to Exhibit 4.16 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 4.5 | Form of TuHURA Biosciences, Inc. Common Stock Warrant issued in TuHURA Note Financing (incorporated by reference to Exhibit 4.17 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 4.6 | Form of Pre-Funded Warrant Certificate (incorporated by reference to Exhibit 4.2 of Amendment No. 1 to TuHURA Biosciences, Inc.’s (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K/A filed with the SEC on August 15, 2019) |
| 4.7 | Form of Investor Warrant (incorporated by reference to Exhibit 4.1 to TuHURA Biosciences, Inc.’s (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K filed with the SEC on April 13, 2022) |
| 4.8 | Form of Investor Warrant (incorporated by reference to Exhibit 4.1 to TuHURA Biosciences, Inc.’s (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K filed with the SEC on April 13, 2022) |
| 4.9 | Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to TuHURA Biosciences, Inc.’s (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K filed with the SEC on April 13, 2022) |
| 4.10 | Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to TuHURA Biosciences, Inc.’s Current Report on Form 8-K filed with the SEC on June 6, 2025) |
| 4.11 | Form of Common Stock Purchase Warrant issued pursuant to Secured Promissory Note and Loan Agreement (incorporated by reference to Exhibit 10.2 to TuHURA Biosciences, Inc.’s Form 8-K filed with the SEC on October 31, 2025) |
| 4.12 | Form of Indenture (incorporated by reference to Exhibit 4.19 to TuHURA Biosciences, Inc.’s Registration Statement on Form S-3 filed with the SEC on November 3, 2025 (Registration No. 333-291239)) |
| 4.13 | Form of Subordinated Indenture (incorporated by reference to Exhibit 4.20 to TuHURA Biosciences, Inc.’s Registration Statement on Form S-3 filed with the SEC on November 3, 2025 (Registration No. 333-291239)) |
| 4.14 | Form of Series A Purchase Warrant (incorporated by reference to Exhibit 4.1 to TuHURA Biosciences, Inc.’s Form 8-K filed with the SEC on December 10, 2025) |
| 4.15 | Form of Series B Purchase Warrant (incorporated by reference to Exhibit 4.2 to TuHURA Biosciences, Inc.’s Form 8-K filed with the SEC on December 10, 2025) |
| 4.16 | Form of Placement Warrant (incorporated by reference to Exhibit 4.3 to TuHURA Biosciences, Inc.’s Form 8-K filed with the SEC on December 10, 2025) |
| 4.17* | Description of the Registrant's Securities |
| 10.1# | Form of Indemnification Agreement by and between TuHURA Biosciences, Inc and each of its directors and executive officers (incorporated by reference to Exhibit 10.2 of TuHURA’s Current Report on Form 8-K filed with the SEC on October 21, 2024) |
| 10.2# | TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 of TuHURA Biosciences, Inc. (f/k/a Kintara Therapeutics, Inc.) Current Report on Form 8-K filed with the SEC on October 21, 2024) |
| 10.3# | Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and Dan Dearborn (incorporated by reference to Exhibit 10.34 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 10.4# | Second Amended and Restated Employment Agreement, dated March 29, 2024, between TuHURA Biosciences, Inc. and James Bianco, M.D (incorporated by reference to Exhibit 10.35 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 10.5† | Exclusive License Agreement, dated March 29, 2019, between Morphogenesis, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc., as amended (incorporated by reference to Exhibit 10.37 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 10.6† | Exclusive License Agreement, dated April 23, 2021, between Morphogenesis, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc., as amended (incorporated by reference to Exhibit 10.38 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368) |
| 10.7† | Restated and Amended Exclusive License Agreement, effective September 7, 2022, between TuHURA Biopharma, Inc. and West Virginia Research Corporation (incorporated by reference to Exhibit 10.39 to the Registration Statement on Form S-4 filed on May 13, 2024 (Registration No. 333-279368)) |
| 10.8# | Form of TuHURA Biosciences, Inc. Stock Option Agreement under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 15, 2024) |
| 10.9# | TuHURA Biosciences, Inc. 2025 Non-Employee Director Compensation Program (incorporated by reference to Exhibit 10.18 to TuHURA Biosciences, Inc.’s Form 10-K filed with the SEC on March 31, 2025) |
| 10.10 | Form of Securities Purchase Agreement, dated as of June 2, 2025, by and among TuHURA Biosciences, Inc. and the investors named therein (incorporated by reference to Exhibit 10.1 to TuHURA Biosciences, Inc.’s Form 8-K filed with the SEC on June 6, 2025) |
| 10.11 | Form of Warrant Amendment Agreement, dated as of September 5, 2025, between TuHURA Biosciences, Inc. and the holders named therein (incorporated by reference to Exhibit 10.2 to TuHURA Biosciences, Inc.’s Form 8-K filed with the SEC on September 11, 2025) |
| 10.12†† | Form of Securities Purchase Agreement, dated as of December 9, 2025, by and among the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to TuHURA Bioscience, Inc.’s Form 8-K filed with the SEC on December 10, 2025) |
| 10.13 | Side Letter Agreement, dated December 9, 2025, between TuHURA Biosciences, Inc. and K&V Investment One LLC (incorporated by reference to Exhibit 10.2 to TuHURA Biosciences, Inc.’s Form 8-K filed with the SEC on December 10, 2025) |
| 19.1 | Insider Trading Policy (incorporated by reference to Exhibit 19.1 to TuHURA Biosciences, Inc. Form 10-K filed with the SEC on March 31, 2025) |
| 21.1 | List of Subsidiaries (incorporated by reference to Exhibit 21.1 to TuHURA Biosciences, Inc’s Current Report on Form S-1 filed with the SEC on August 12, 2025) |
| 23.1* | Consent of Cherry Bekaert LLP, independent registered public accounting firm. |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 31.2 * | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1** | Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 97.1* | TuHURA Biosciences, Inc. Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to TuHURA Biosciences, Inc.’s Form 10-K filed March 31, 2025) |
| 101.INS | XBRL Instance Document |
| 101.SCH | SBRL Schema Document |
| 101.CAL | Calculation Linkbase Document |
| 101.DEF | Definition Linkbase Document |
| 101.LAB | XBRL Label Linkbase Document |
| 101.PRE | XBRL Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
† Confidential treatment is requested for certain confidential portions of this exhibit pursuant to Rule 24b-2 under the Exchange Act. In accordance with Rule 24b-2, these confidential portions have been omitted from this exhibit and filed separately with the Securities and Exchange Commission.
†† Schedule has been omitted pursuant to Item 601(a)(5) of Regulation S-K. TuHURA hereby undertakes to furnish copies of any of the omitted schedules upon request by the Securities and Exchange Commission.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.